Gastric cancer (GC) is the third leading cause of cancer mortality worldwide. Currently, GC is the fifth most frequently diagnosed cancer, and it is the third most lethal cancer worldwide. Each year, almost one million new cases of GC are diagnosed and more than 700,000 people die of this disease, thereby representing ~10% of the deaths due to cancer worldwide.GC is a complex and multifactorial disease. There are many inherited and environmental factors that play a role in GC carcinogenesis, including the genetic characteristics of the host, infectious agents (such as Helicobacter pylori and Epstein Barr), and dietary habits.
Major features and salient genomic alterations that have been associated with each molecular subtype of GC proposed by the TCGA. CIMP: CpG island methylator phenotype; EBV: Epstein-Barr virus; MSI: Microsatellite instability; GS: Genomically stable; CIN: Chromosomal instability.Signaling pathways (including ErbB pathway, VEGF pathway, PI3K/AKT/mTOR pathway, HGF/MET pathway and Hedgehog Pathway) and genetic alterations that may represent potential therapeutic targets for GC.

References

1.Ismael Riquelme,et al. Oncotarget, Vol. 6, No. 28.